View Older Stories

Oct 24, 2025 07:30AM MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Oct 16, 2025 04:05PM MIRA Pharmaceuticals sells 1.75M shares at 66% premium

Oct 16, 2025 07:30AM MIRA Pharmaceuticals reports oral Mira-55 outperformed morphine in pain study

Oct 16, 2025 07:30AM MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Sep 30, 2025 07:31AM MIRA Pharmaceuticals completes SKNY acquisition, adds $5M in securities

Sep 30, 2025 07:30AM MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Sep 22, 2025 08:02AM MIRA reports positive Phase 1 trial results for ketamine analog Ketamir-2

Sep 22, 2025 08:00AM MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Sep 16, 2025 07:30AM Mira Pharma (MIRA) Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 16, 2025 07:30AM MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 15, 2025 04:06PM MIRA Pharmaceuticals reports positive preclinical PTSD data for Ketamir-2

Sep 12, 2025 07:30AM MIRA Pharmaceuticals shareholders approve SKNY acquisition

Sep 12, 2025 07:30AM MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Aug 19, 2025 08:30AM MIRA Pharmaceuticals completes Phase 1 trial stage for oral Ketamir-2

Aug 19, 2025 08:30AM MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Aug 12, 2025 08:32AM MIRA's Ketamir-2 study accepted for publication in peer-reviewed journal

Aug 12, 2025 08:30AM MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabal

Jul 30, 2025 07:30AM MIRA Pharmaceuticals topical Ketamir-2 matches morphine in preclinical study

Jul 30, 2025 07:30AM MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

Jul 29, 2025 07:31AM MIRA Pharmaceuticals receives FDA clearance for Ketamir-2 neuropathic pain trial

Jul 29, 2025 07:30AM MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

Jul 11, 2025 08:00AM MIRA reports anxiety reversal in animal study of obesity drug

Jul 11, 2025 08:00AM MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Jul 3, 2025 08:02AM Mira Pharma (MIRA) Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jul 3, 2025 08:00AM MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jun 30, 2025 08:00AM MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisitio

Jun 25, 2025 08:00AM MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

Jun 18, 2025 08:31AM Mira Pharma's (MIRA) Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

Jun 18, 2025 08:30AM MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

Jun 17, 2025 04:06PM Mira Pharma (MIRA) says Ketamir-2 has been accepted for publication in Frontiers in Pharmacology

May 28, 2025 08:30AM MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 8, 2025 08:04AM Mira Pharma (MIRA) Announces Board Approval of SKNY Acquisition

May 8, 2025 08:00AM MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 6, 2025 08:02AM Mira Pharma (MIRA) Reports No Brain Toxicity in FDA-Required Study of Ketamir-2

May 6, 2025 08:00AM MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

Apr 23, 2025 08:04AM Mira Pharma (MIRA) Reports Positive In Vitro Drug Release Data for Topical Ketamir-2

Apr 23, 2025 08:00AM MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 16, 2025 08:03AM Mira Pharma (MIRA) Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 16, 2025 08:00AM MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 1, 2025 08:00AM MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Mar 24, 2025 07:33AM Mira Pharma (MIRA) Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion

Mar 24, 2025 07:30AM MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 13, 2025 08:00AM MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 4, 2025 08:02AM Mira Pharma (MIRA) Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Mar 4, 2025 08:00AM MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Dec 19, 2024 09:02AM Mira Pharma (MIRA) Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 19, 2024 09:00AM MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 10, 2024 08:34AM Mira Pharma (MIRA) Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Dec 10, 2024 08:30AM MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Nov 20, 2024 07:47AM Mira Pharma (MIRA) Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

View Older Stories